TerminatedNCT06375772Updated Nov 19, 2024

A Controlled Human Rhinovirus Infection Study of 2-Deoxy-D-Glucose in Healthy Adults

A Phase 2 interventional study of 2-Deoxy-D-glucose and Placebo in Acute Nasopharyngitis, sponsored by G.ST Antivirals GmbH. Terminated at 1 site in Netherlands. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by G.ST Antivirals GmbH · Phase 2, Interventional, and Prevention

Why this study was terminated

Re-calculated sample size

Phase: Phase 2
Study type: Interventional
Enrollment: 64
Allocation: Randomized
Ages: 18 Years to 64 Years
Sex: All

Study summary

2-DG-02 is a randomized, placebo-controlled, double-blind Phase 2 study to investigate the efficacy and safety of 2-Deoxy-D-Glucose as a pre-exposure prophylaxis using the rhinovirus challenge model in healthy study participants.

Read the detailed description

2-DG-02 is a randomized, placebo-controlled, double-blind Phase 2 study using the rhinovirus challenge model in healthy study participants aged 18 to 64 years.

The primary objective is to confirm the efficacy of 2-DG compared to placebo for the prevention of rhinovirus-associated illness.

Secondary objectives are

to evaluate the effect of 2-DG on the occurrence and course of rhinovirus infection
to evaluate the effect of 2-DG on the severity of symptoms of rhinovirus infection
to evaluate safety and tolerability of 2-DG administrated over 1 week in the presence of rhinovirus exposure
to evaluate pharmacokinetics of 2-DG
128 subjects, who have been pre-screened and found to be seronegative to rhinovirus type 39, are randomized 1:1 to either 2-DG (pre-exposure prophylaxis) or placebo the day prior to inoculation. Subjects receive 2-DG or placebo starting from the day prior to inoculation until 5 days post inoculation.

Interim safety and efficacy reviews are performed by a Safety Monitoring Committee.

Conditions studied

Acute Nasopharyngitis

Browse trials for

Common Cold 178

Who can participate

Ages eligible: 18 Years to 64 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Healthy male or female subjects 18 to 64 (inclusive at screening) years of age.
Women of childbearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception until end of study.
Signed informed consent form prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

Active smoker or history of smoking > 5 pack years.
Upper or lower respiratory tract infection or febrile illness
Presence (at screening) of serum RV-39 neutralizing antibody titer at greater than one in four (1:4) dilution.
Nasopharyngeal swab indicative for Influenza or SARS-CoV2 infection by rapid antigen test at baseline.
Prior inoculation with a virus from the same virus family as the challenge virus.
Any anatomic or neurologic abnormality impairing the gag reflex, or associated with an increased risk of aspiration, or any abnormality significantly altering the anatomy of the nose or nasopharynx in a substantial way that may interfere with the aims of the study and in particular any of the nasal assessments or viral challenge.
Positive Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibody (HCV Ab), or human immunodeficiency virus antibody (HIV Ab) at screening.
Any confirmed or suspected disease or condition associated with immune system impairment, including auto-immune diseases, asplenia or recurrent severe infections.
Active allergic rhinitis or hay fever.
Medical history or active asthma or chronic obstructive pulmonary disease (COPD) or any other pulmonary disease deemed by the investigator to increase the risk of participating in the study.
Active nasal disease, e.g., nasal polyposis, significant septal deviation, chronic rhinosinusitis, etc.
Frequent epistaxis or nasal sinus surgery within 3 months before baseline.
Females: Pregnant, breast-feeding or intentions to become pregnant during the study.
Evidence or history of drug or alcohol abuse.
Positive test for drugs of abuse at screening or prior to study drug administration.
Use of any prescribed or non-prescribed medication (except for contraceptives, paracetamol) within 1 week or less than 5 half-lives (whichever is longer) prior to the first administration of investigational product.
Use of any over the counter cold prophylaxis products including nasal sprays, C-vitamins, zinc or Echinacea within 2 weeks prior to the first administration of investigational product.
Participation in an investigational medical product, vaccine or device study within 3 months or 5 half-lives prior to the study period (whichever is longer), or more than 4 times in the past year.
Hypersensitivity/allergy to any of the investigational product ingredients.
Individuals with close contact to at risk patient group (infants less than 3 years, the extremely elderly >80 years or infirm, pregnant women, patients with severe lung disease(e.g., asthma/cystic fibrosis (CF)/COPD), patients with primary or secondary immunodeficiencies or ongoing immunosuppressive therapy).
Any clinically relevant abnormal history, physical finding, 12-lead safety ECG, vital signs, laboratory value at screening or any known factor that could interfere with the objectives of the trial or the safety of the volunteer. In the case of uncertain or questionable results, tests performed during screening may be repeated before inclusion to confirm eligibility or judged to be clinically irrelevant.

Study design

Phase: Phase 2
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Triple (Participant, Investigator, Outcomes assessor)
Enrollment: 64 participants (actual)

Study arms

Active comparator
Study Drug
Each subject receives a multiple dose of a 3.5% 2-Deoxyglucose as nasal spray solution. The maximum daily dose is 56 mg/day if applied 4 times/day, over 7 days.
Drug: 2-Deoxy-D-glucose
Placebo comparator
Placebo
Each subject receives a multiple dose of placebo as nasal spray solution. The dose is corresponding to the amount of solution needed in the serum group.
Other: Placebo

Interventions

Drug2-Deoxy-D-glucose
Intranasal administration
Also known as: 2-Deoxyglucose, 2-DG
OtherPlacebo
Intranasal administration

What researchers measure

Primary outcomes

The difference in the rate of rhinovirus-associated illness between 2-DG and placebo
Difference in the rate of symptomatic illness and laboratory-confirmed infection
Time frame: baseline until day 22

Secondary outcomes

Number of infected subjects
Difference in the number of subjects with laboratory-confirmed infections. A laboratory-confirmed infection is identified either by isolating rhinovirus on at least one day after the virus challenge using qPCR or by a 4-fold increase in neutralizing antibody titer to RV-39 from acute (day -1) to convalescent sera (day 22) using the neutralizing assay.
Time frame: baseline, days 2-22 after start of dosing
Difference in percent of infected subjects
Difference in percentage of subjects with laboratory-confirmed infections. A laboratory-confirmed infection is identified either by isolating rhinovirus on at least one day after the virus challenge using qPCR or by a 4-fold increase in neutralizing antibody titer to RV-39 from acute (day -1) to convalescent sera (day 22) using the neutralizing assay.
Time frame: baseline, days 2-22 after start of dosing
Difference in percent of days virus positive
Difference in the percentage of days with a positive virus load. A positive virus load is determined by isolating rhinovirus on at least one day following the virus challenge, either using qPCR or a TCID50 assay.
Time frame: days 2-6
Difference in peak nasal virus load
Virus load is confirmed by isolating rhinovirus on at least one day after the virus challenge, using either qPCR or a TCID50 assay.
Time frame: days 2-6
Difference in AUC nasal virus load
Difference in AUC log 10 nasal virus load. Virus load is confirmed by isolating rhinovirus on at least one day after the virus challenge, using either qPCR or a TCID50 assay.
Time frame: days 2-6
Difference in Total Jackson Symptom Score
The difference of total Jackson Symptom Score (4 point-liters scales from 0 to 3) where a lower score means a better outcome.
Time frame: days 2-6 after start of dosing
Duration of illness
In study participants with RAI duration of illness is the time to the first day of the two consecutive days with a total symptom score ≤ 1 that occurs after the subject has met the symptom criteria for a RAI. A lower duration means a better outcome.
Time frame: days 2-15 after start of dosing
Difference in percent of days Jackson Symptom Score positive
Percentage of days with positive Jackson Symptom Score ( score \>2), where a lower percentage means a better outcome compared to placebo.
Time frame: days 2-6 after start of dosing
Difference in Peak Jackson Symptom Score
The highest daily total of all patient-reported symptoms on the Jackson Cold Scale (4 point-liters scales from 0 to 3 where a lower score means a better outcome compared to placebo).
Time frame: days 2-6 after start of dosing
Difference in peak total WURSS-21
The highest daily total of all patient-reported symptoms on the WURSS-21 questionnaire (8-point Likert scales from 0 to 7) where a lower score means a better outcome compared to placebo.
Time frame: days 2-6 after start of dosing
Difference in AUC total WURSS-21
Difference in AUC total WURSS-21 based a score recorded through the WURSS-21 questionnaire (8-point Likert scales from 0 to 7) where lower score means a better outcome compared to placebo.
Time frame: days 2-6 after start of dosing
Occurrence of adverse events (AEs) and adverse drug-reactions (ADRs)
Number of AEs and ADRs assessed by type, frequency and severity graded as per Common Terminology Criteria for Adverse Events (CTCAE).
Time frame: from screening (day -56) until end of study (day 22± 2) after start of dosing
Biodistribution of multiple doses of 2-DG in plasma samples
Analysis of 2-DG concentrations in plasma samples measured by LCMS (μg/ml).
Time frame: baseline, days 6 and 22± 2 after start of dosing
Biodistribution of multiple doses of 2-DG in nasal wash samples
Analysis of 2-DG concentrations in nasal wash samples measured by LCMS (μg/ml).
Time frame: baseline, days 2-6 and day 22± 2 after start of dosing

Study locations

1 site

Centre for Human Drug Research
Leiden, 2333, Netherlands

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Registry details

Key details

Study ID: NCT06375772
Lead sponsor: G.ST Antivirals GmbH
Responsible party: Sponsor
First posted: Apr 19, 2024
Start date: Apr 2, 2024
Primary completion: Aug 13, 2024
Completion: Aug 13, 2024
Last update: Nov 19, 2024

Study contacts

Ingrid de Visser-Kamerling, PhD

principal investigator · Centre for Human Drug Research

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Nasopharyngitis

Other studies from this sponsor

G.ST Antivirals GmbH

Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy VolunteersCompletedNCT05314933Phase 1

Start the discussion